Tumor microenvironment

Translational Research in Oncology -- Innovations in Model Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, December 2, 2022

TORONTO, Dec. 2, 2022  /PRNewswire-PRWeb/ -- To develop the next generation of targeted cancer therapies, researchers need cancer models that can stand in as true proxies for human disease. Traditional research models commonly used in commercial applications have a place in screening and can provide directional information about potential therapeutic responses. However, they do not replicate the heterogenous biology and complex network of dysregulated pathways that characterize real-life human tumors. In fact, most models used in preclinical drug development fail to address the importance of tumor microenvironment, despite its well-established role in druggability and immune response. Translational research in oncology can greatly benefit from improvements to these models.

Key Points: 
  • Translational research in oncology can greatly benefit from improvements to these models.
  • Translational research success is largely dependent upon selecting or sometimes custom-developing the most appropriate preclinical model to assess a candidate's therapeutic response.
  • Register to learn about the innovations in preclinical model development for translational research in oncology.
  • For more information, or to register for this event, visit Translational Research in Oncology Innovations in Model Development .

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, December 1, 2022

Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.

Key Points: 
  • Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.
  • We are very pleased to be making progress on our CTX-471 clinical program with dosing of the first patient in the combination arm with KEYTRUDA, said Thomas Schuetz, M.D., Ph.D., Chief Executive Officer and Scientific Founder of Compass.
  • CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable

Retrieved on: 
Thursday, December 1, 2022

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

Key Points: 
  • Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
  • Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site.
  • However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains.
  • At ~4-6 kDa, these are three times smaller than a camelid nanobody, and are the smallest known antibody fragment.

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Retrieved on: 
Thursday, December 1, 2022

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate (ADC) product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer.

Key Points: 
  • We are thrilled to receive two nearly simultaneous IND clearances from the FDA, representing a major moment as we transition to a clinical stage company demonstrating the operational prowess of our team, said Lara Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • Jay Feingold, M.D., Ph.D., Chief Medical Officer of Pyxis Oncology, added, "We are excited to advance multiple programs to the clinic.
  • Both product candidates could potentially be applied to a broad range of tumors and address a significant need in the community.
  • Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers.

Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

Retrieved on: 
Thursday, December 1, 2022

For more information on Kineta, please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .

Key Points: 
  • For more information on Kineta, please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .
  • KVA12123 (formerly referred to as KVA12.1) is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.
  • It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
  • KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Retrieved on: 
Thursday, December 1, 2022

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.
  • IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment.
  • By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Retrieved on: 
Wednesday, November 30, 2022

I am pleased to announce the appointment of Lou as a member of our Board, said Andy Arno, Chair of Oncocytes Board of Directors.

Key Points: 
  • I am pleased to announce the appointment of Lou as a member of our Board, said Andy Arno, Chair of Oncocytes Board of Directors.
  • Mr. Silverman serves as a board member at a venture backed health care-oriented fin-tech company and a hospital system based in the Northeast.
  • Mr. Silverman earned his BA in American Studies (cum laude) from Amherst College and his MBA from Harvard Business School.
  • I am honored to be joining the Oncocyte Board of Directors," said Mr. Silverman.

Oncocyte Announces Executive Leadership Changes

Retrieved on: 
Wednesday, November 30, 2022

I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.

Key Points: 
  • I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.
  • On behalf of the Board, I want to wish Ronnie all the best in his future endeavors and to thank him for his many contributions to Oncocyte, including his leadership and mentorship of Josh, said Andy Arno, Chairman of the Board.
  • The Board intends to begin a search for a permanent Chief Executive Officer shortly, and expects that Josh will be a candidate.
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.